Data are available from <https://figshare.com/articles/CANCERTOPE_MUTATION_DATASET_txt/4176558>

Introduction {#sec001}
============

Worldwide, cancer is one of the most prominent cause of immature deaths every year \[[@pone.0166372.ref001]\]. In addition to millions of deaths each year, all countries are spending billions of dollars on treatment of cancer patients. In past, effective vaccines have been developed successfully against number of frightening diseases (e.g. small pox, polio); saving millions of lives. Subsequently, it is extremely important to develop effective vaccines against cancer to protect the human population from this awful disease. In this direction, researchers have got limited success in designing vaccine against cancers particularly against cancer-inducing viruses \[[@pone.0166372.ref002],[@pone.0166372.ref003]\]. There are a number of hurdles in developing cancer vaccines that includes cross-reactivity, tolerance and insufficient immune response \[[@pone.0166372.ref004]\]. Similarly, the identification of mutations shared across wide range of cancer patients is also a challenge \[[@pone.0166372.ref005],[@pone.0166372.ref006]\]. However, with advent of high throughput sequencing and assay techniques, different authors have made an attempt to investigate important shared mutations in various types of cancers \[[@pone.0166372.ref007],[@pone.0166372.ref008]\]. Furthermore, in order to design a successful vaccine, it is important to identify cancer-specific antigens or antigenic regions that can induce immune system specifically against cancerous cells. These antigens and antigenic regions are called neoantigens and neoepitopes respectively. In past, number of experimental techniques has been developed to identify vaccine candidates (e.g., neoantigens, neoepitopes) for designing cancer vaccines \[[@pone.0166372.ref009],[@pone.0166372.ref010]\].

Although there are reports of identification of vaccine candidates at genome scale, but the task is demanding because experimental techniques are costlier and time consuming with large amount of samples. In order to overcome the limitations of experimental techniques, numerous computational tools have been developed for designing vaccines or immunotherapy against cancer. Broadly, these computational tools can be divided in two categories: i) methods for predicting epitopes, and ii) prediction of potential vaccine candidates for cancer. In past, numerous direct or indirect epitope predictions have been developed for predicting antigenic regions that can activate B-cell, T-helper and cytotoxic T-cells \[[@pone.0166372.ref011],[@pone.0166372.ref012]\]. In case of prediction of cancer vaccine targets, first cancer-specific regions are identified and then their immunogenic properties are predicted. Warren *et al*. (2010) identified mutated regions in antigens/proteins generated due to somatic mutations (missense, frame shift, insertion, and deletion) in human tumors \[[@pone.0166372.ref011]\]. They predicted HLA class I binders in these mutated regions and identified 159 potential vaccine candidates. Similarly, Khalili *et al*. (2012) predicted HLA-A and B binders in mutated region of 312 genes; generated due to missense mutations \[[@pone.0166372.ref013]\]. Brown *et al*. identified immunogenic mutations in the form of HLA class I binders from sequencing data of 515 patients \[[@pone.0166372.ref014]\]. In this study, authors endeavored to correlate the presence of immunogenic missense mutations with the survival of patients. Recently, Rajasagi *et al*. proposed 22 HLA class I binders generated from missense mutations through a developed pipeline for 91 chronic lymphocytic leukemias \[[@pone.0166372.ref015]\]. In most of the above studies, authors predicted only HLA class I binders or cytotoxic T-cell (CTL) epitopes.

There are several computational tools for the prediction of HLA binding peptides and T-cell epitopes and B cell epitopes, which can be used for the prediction of immunogenic mutated regions in an antigen. However, there is a necessity for a streamlined computational tool that allows users to identify immunogenic mutations and the predicted cancer epitopes. One of the major limitations of existing computational tools for predicting cancer vaccine candidates is that they do not predict B-cell or T-helper epitopes. In addition, there is no specific computation resource for predicted cancer epitopes in user-specified genome. Aim of this study is complementing existing methods and to address unresolved issues. We analyzed mutational profile of 905-cancer cell lines and identified neoepitopes that can activate different arms of immune system. This information has been compiled in the form of a database so that the user can access cancer-specific epitopes for any cancer cell line. In addition, fully and partially personalized pipelines have been integrated in this database to facilitate scientific community. In brief, the study illustrates exclusive evaluation of immune epitopes on the mutational landscape of a large number of cancer cell lines (<https://figshare.com/articles/CANCERTOPE_MUTATION_DATASET_txt/4176558>) and eventually postulates a workbench, named Cancertope for designing neoepitope-based personalized vaccines/immunotherapies (<http://crdd.osdd.net/raghava/cancertope/>).

Results {#sec002}
=======

Analysis of Vaccine Targets {#sec003}
---------------------------

The current study is based on 60 vaccine candidates, 26 reported from the analysis of NGS data from CCLE database \[[@pone.0166372.ref016]\] and remaining 34 candidates from CanProVar \[[@pone.0166372.ref017]\] based on their association with cancer. The 26 genes (vaccine candidates) were selected from CCLE as they frequently mutate in different types of cell lines (see [Methods](#sec014){ref-type="sec"} section). The distribution and types of mutations were then analyzed in vaccine candidates, which further depicted the prominence of missense mutation type ([Fig 1](#pone.0166372.g001){ref-type="fig"}). Similarly, the frame shift mutations in a few key genes like *PRKDC*, *RECQL4*, *PDE4DIP*, and *CTBP2* were found in harmony with a large number of cell lines. Also, the in-frame insertions and deletions were very profound in genes like *AKAP12*, *NR1H2*, *GPR112*, and *MAP3K1*. All these genes in the study are being referred to as cancer sensitive genes since they possess higher probability to be associated with cancer on encountering mutations. In other words, a gene is called cancer-sensitive, if the mutations in that gene have high propensity of being cancer-associated.

![Frequency and type of mutations reported for each vaccine candidate.\
Each numerical value representing the number of mutations across different cell lines in a vaccine candidate, for instance, vaccine target PRKDC has been mutated 842 times (frame shift insertions) in the different cell lines.](pone.0166372.g001){#pone.0166372.g001}

Furthermore, [Table 1](#pone.0166372.t001){ref-type="table"} presents 34 vaccine targets possessing mutations that exhibit higher probability of transforming a normal cell into a cancerous cell as selected from CanProVar. Among these vaccine candidates, mutations in targets like PTEN \[[@pone.0166372.ref018]\], TP53 \[[@pone.0166372.ref018]\], BRAF \[[@pone.0166372.ref019]\], EGFR \[[@pone.0166372.ref020]\] and c-KIT \[[@pone.0166372.ref021],[@pone.0166372.ref022]\] have already been reported in earlier studies to be highly carcinogenic and proposed to be targeted for intending immunotherapies. These analyses support our criteria of selection of generalized vaccine candidates. To further broaden the perspective of functional analysis, the cancer sensitive genes were compared with all other genes on the basis of their gene ontologies. The analyses uncovered interesting observations suggesting involvement of cancer sensitive proteins is somehow greater in the apoptotic processes, biological regulation, catalytic and binding activities as compared to the other proteins ([Fig 2](#pone.0166372.g002){ref-type="fig"} and [S1 Fig](#pone.0166372.s001){ref-type="supplementary-material"}).

10.1371/journal.pone.0166372.t001

###### Number of deleterious mutations (f~D~), polymorphism/neutral variants (f~P~) and cancer association (f~D~/f~P~) in each vaccine target.
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  Target    f~D~   f~P~   f~D~/f~P~   Family/subfamily of target/protein
  --------- ------ ------ ----------- ------------------------------------------------------------------------------------------------------
  PTEN      389    1      389         NA
  TP53      1353   7      193.3       P53_family
  CTNNB1    132    1      132         Beta-catenin_family
  BRAF      99     1      99          Protein_kinase_superfamily,\_TKL_Ser/Thr_protein_kinase_family,\_RAF_subfamily
  NF2       74     1      74          NA
  EGFR      188    3      62.7        Protein_kinase_superfamily,\_Tyr_protein_kinase_family,\_EGF_receptor_subfamily
  SMAD4     107    2      53.5        Dwarfin/SMAD_family
  VHL       272    6      45.3        NA
  KIT       131    3      43.7        Protein_kinase_superfamily,\_Tyr_protein_kinase_family,\_CSF-1/PDGF_receptor_subfamily
  PIK3CA    174    4      43.5        PI3/PI4-kinase_family
  NRAS      36     1      36          Small_GTPase_superfamily,\_Ras_family
  MSH2      103    5      20.6        DNA_mismatch_repair_MutS_family
  GATA1     20     1      20          NA
  MLH1      118    6      19.7        DNA_mismatch_repair_MutL/HexB_family
  FBXW7     67     4      16.8        NA
  MEN1      49     3      16.3        NA
  FGFR3     31     2      15.5        Protein_kinase_superfamily,\_Tyr_protein_kinase_family,\_Fibroblast_growth_factor_receptor_subfamily
  TSHR      46     3      15.3        G-protein_coupled_receptor_1\_family,\_FSH/LSH/TSH_subfamily
  JAK2      40     3      13.3        Protein_kinase_superfamily,\_Tyr_protein_kinase_family,\_JAK_subfamily
  RB1       102    8      12.8        Retinoblastoma_protein\_(RB)\_family
  PDGFRA    35     3      11.7        Protein_kinase_superfamily,\_Tyr_protein_kinase_family,\_CSF-1/PDGF_receptor_subfamily
  NF1       65     6      10.8        NA
  FGFR2     43     4      10.8        Protein_kinase_superfamily,\_Tyr_protein_kinase_family,\_Fibroblast_growth_factor_receptor_subfamily
  FLT3      35     4      8.8         Protein_kinase_superfamily,\_Tyr_protein_kinase_family,\_CSF-1/PDGF_receptor_subfamily
  CDH1      68     8      8.5         NA
  TNFAIP3   31     4      7.8         Peptidase_C64_family
  CBL       30     4      7.5         NA
  RET       58     8      7.3         Protein_kinase_superfamily,\_Tyr_protein_kinase_family
  MSH6      40     8      5           DNA_mismatch_repair_MutS_family
  ERBB2     29     6      4.8         Protein_kinase_superfamily,\_Tyr_protein_kinase_family,\_EGF_receptor_subfamily
  MET       23     5      4.6         Protein_kinase_superfamily,\_Tyr_protein_kinase_family
  ABL1      23     7      3.3         Protein_kinase_superfamily,\_Tyr_protein_kinase_family,\_ABL_subfamily
  ALK       27     9      3           Protein_kinase_superfamily,\_Tyr_protein_kinase_family,\_Insulin_receptor_subfamily
  ATM       134    52     2.6         PI3/PI4-kinase_family,\_ATM_subfamily

![The functional characterization of cancer-sensitive and other proteins based on their gene ontologies.](pone.0166372.g002){#pone.0166372.g002}

Expression Analysis of Cancer Vaccine Candidates {#sec004}
------------------------------------------------

As stated earlier, cancer vaccine candidates were selected on the basis of their mutation frequency in cancer cell lines and their level of association with cancer. Next, the expression profile of these genes was examined in all available cancer cell lines. As displayed in [Table 2](#pone.0166372.t002){ref-type="table"}, most of the vaccine candidates were highly expressed in a large number of cell lines. Since, the attained expression data ranged from 2 to 15, the expression values were randomly divided into four bins for well-defined understanding and the genes with expression values \> = 9 were anticipated as highly expressed genes. With this assumption, it was perceived that the candidate genes i.e. *HSP90B1*, *MLH1*, *MSH6*, *PRKDC*, *MSH2*, and *AKAP9* are highly expressed in more than 700 cell lines.

10.1371/journal.pone.0166372.t002

###### Expression analysis depicting number of cell lines with expression more than a given cutoff (e.g., 3, 7, 9) for each antigen.
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  Target    \>= 3   \>= 7   \>= 9   \>= 12
  --------- ------- ------- ------- --------
  AAK1      901     0       0       0
  ABL1      901     900     595     0
  AKAP12    901     509     294     8
  AKAP9     901     900     723     2
  ALK       901     23      12      1
  ALPK2     901     179     92      1
  ATM       901     816     165     0
  BRAF      901     282     1       0
  CARD10    901     591     109     0
  CBL       901     754     4       0
  CDH1      901     358     217     0
  CHD1      901     901     644     0
  CREB3L2   901     849     424     1
  CTBP2     901     802     638     0
  CTNNB1    901     807     60      0
  EGFR      901     318     21      0
  ERBB2     901     368     39      14
  FBXW7     NA      NA      NA      NA
  FGFR2     901     164     34      1
  FGFR3     901     88      6       0
  FLT3      901     35      27      3
  FMN2      901     101     22      0
  GATA1     901     19      17      0
  GPR112    901     0       0       0
  HSP90B1   901     901     897     282
  JAK2      901     68      7       1
  KIT       901     170     82      12
  MAML2     901     49      0       0
  MAP3K1    901     393     28      0
  MAP3K4    901     900     678     0
  MEN1      NA      NA      NA      NA
  MET       NA      NA      NA      NA
  MLH1      901     875     861     2
  MLL3      0       0       0       0
  MSH2      901     887     731     0
  MSH3      901     555     1       0
  MSH6      901     892     820     7
  MYLK      901     473     286     26
  MYST4     NA      NA      NA      NA
  NCOA3     901     825     156     0
  NF1       901     264     2       0
  NF2       901     19      0       0
  NR1H2     901     161     0       0
  NRAS      901     891     675     4
  PDE4DIP   901     198     12      0
  PDGFRA    901     115     73      9
  PIK3C2G   901     14      2       0
  PIK3CA    901     856     89      0
  PRKDC     901     901     815     3
  PTEN      901     834     315     0
  RB1       901     674     26      0
  RECQL4    901     804     39      0
  RET       901     52      15      0
  SMAD4     901     575     5       0
  TNFAIP3   901     596     252     9
  TNRC6B    901     803     8       0
  TP53      901     597     75      0
  TSHR      901     22      3       0
  TTBK1     901     0       0       0
  VHL       901     499     5       0

For example, *HSP90B1* has 282 cell lines having expression greater or equal to 12.

Identification of Neopeptides {#sec005}
-----------------------------

After scrutinizing 60 potential vaccine candidates, the next challenge was to identify cancer-specific regions/peptides in these vaccine candidates. Therefore, overlapping 9-mer peptides for each of the vaccine candidates ([Table 3](#pone.0166372.t003){ref-type="table"}) were created and different filters were applied in order to identify cancer-specific peptides generated due to cancer-associated mutations. These filters refined the dataset by eliminating all those peptides whose identical sequence maps to the genome of healthy individuals. The criteria adopted for removing identical peptides focused on i) reference protein, 2) reference proteome, 3) 1000 Genomes-based variants of the same antigen and 4) 1000 Genomes-based proteomes. It was observed that the candidates such as TP53, MLL3, PDE4DIP, PRKDC and certain others have the highest number of unique neopeptides, not present in reference proteome or 1000 Genomes-based proteomes.

10.1371/journal.pone.0166372.t003

###### Total number of generated neopeptides (9-mer peptides) in each vaccine candidate and number of neopeptides after applying different filters.
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  Vaccine Candidate   Total 9-mer   Reference Protein   Reference Proteome   1000-Genome Proteomes
  ------------------- ------------- ------------------- -------------------- -----------------------
  TP53                2589          2204                2204                 2204
  MLL3                6570          1671                1671                 1670
  PDE4DIP             3468          1130                1121                 1013
  PRKDC               5269          1149                1149                 1149
  TNRC6B              2730          905                 905                  886
  AKAP9               4873          974                 974                  938
  ATM                 4016          968                 968                  968
  GPR112              4061          989                 989                  989
  FMN2                2322          850                 805                  797
  NF1                 3650          819                 819                  810
  MYST4               2705          668                 668                  639
  PTEN                1148          753                 753                  753
  CTBP2               1550          573                 573                  573
  ALK                 2185          573                 573                  557
  MYLK                2512          615                 615                  596
  ALPK2               2765          603                 603                  603
  AKAP12              2265          491                 491                  430
  MAML2               1536          443                 443                  440
  MAP3K4              2078          482                 482                  480
  PIK3CA              1573          513                 513                  513
  SMAD4               1005          461                 461                  460
  RECQL4              1658          458                 458                  431
  PDGFRA              1563          482                 473                  461
  MSH6                1839          487                 487                  459
  CHD1                2209          507                 507                  490
  PIK3C2G             1881          444                 426                  418
  CDH1                1279          405                 405                  405
  EGFR                1628          426                 426                  426
  FGFR3               1190          390                 390                  380
  MSH3                1489          363                 363                  334
  FBXW7               1111          412                 412                  409
  MET                 1813          413                 413                  401
  TNFAIP3             1139          357                 357                  348
  CTNNB1              1122          349                 349                  349
  RB1                 1241          321                 321                  321
  RET                 1459          353                 353                  353
  NCOA3               1701          305                 305                  305
  KIT                 1280          312                 312                  303
  MLH1                1063          315                 315                  306
  MAP3K1              1835          331                 330                  322
  BRAF                1106          348                 348                  345
  FLT3                1290          305                 305                  295
  FGFR2               1102          288                 288                  288
  ABL1                1400          259                 259                  259
  JAK2                1379          255                 255                  255
  MSH2                1198          272                 272                  254
  CARD10              1264          241                 241                  232
  TSHR                1017          261                 261                  261
  ERBB2               1482          235                 235                  232
  CBL                 1123          225                 225                  223
  NRAS                380           199                 199                  189
  MEN1                804           197                 197                  197
  TTBK1               1483          189                 189                  180
  NF2                 798           211                 211                  201
  GATA1               569           164                 164                  164
  HSP90B1             980           185                 185                  185
  CREB3L2             670           158                 158                  158
  NR1H2               592           139                 139                  138
  AAK1                1080          132                 132                  122
  VHL                 297           92                  92                   92

The filters remove neoepitopes present in reference protein, human reference proteome and 1000 Genomes-based proteomes.

Evaluating Neopeptides as Neoepitopes {#sec006}
-------------------------------------

The generated neopeptides in the study were further analyzed for their roles as neoepitopes, i.e. antigenic region of nine amino acids specifically found in cancer antigens that can substantially activate different arms of the human immune system. In order to identify neoepitopes, different prediction tools were used for estimation of distinct epitopes \[[@pone.0166372.ref023],[@pone.0166372.ref024],[@pone.0166372.ref025],[@pone.0166372.ref026],[@pone.0166372.ref027]\]. Among all the tissue of origins, cell lines were explored for tissue-specific neoepitopes. Most frequent (top 10) neoepitopes along with their immunological potential are shown in the [S1 Table](#pone.0166372.s002){ref-type="supplementary-material"}. Interestingly, "IRKQQQQQE" neoepitope, which was generated de novo because of mutation in NR1H2 protein, was frequently observed in hematopoietic, lung, kidney, biliary tract, CNS bone, ovary, pancreas, prostate and large intestine tissues related cell lines. Moreover, it also harbors B cell epitope and is a binder for MHC I, MHC II. Similarly, mutation in same gene and cell lines generated "QQQQQESQS" which is a B cell epitope. Furthermore, in case of solid tumors like large intestine, the total number of neoepitopes was the highest in MLL3 and PDE4DIP targets whereas for hematopoietic tumors, TP53 and PDE4DIP were found to have the highest number of neoepitopes ([S2 Table](#pone.0166372.s003){ref-type="supplementary-material"}). The analysis of 60 vaccine candidates provided 38 promiscuous epitopes that have the ability to induce all arms of the immune system ([S3 Table](#pone.0166372.s004){ref-type="supplementary-material"}). Additionally, there were interesting outcomes from each individual algorithm of our pipeline that has been complied in the resource. For example, PRKDC has 5 or more positive neoepitopes predicted using CTLPred and nHLAPred, which were present in more than 800 unique cell lines ([S4](#pone.0166372.s005){ref-type="supplementary-material"} and [S5](#pone.0166372.s006){ref-type="supplementary-material"} Tables). Also, there were more than 15 neopeptides found to be HLA class I binders (using ProPred1) from RECQL4 and PRKDC, which were present in more than 600 cell lines ([S6 Table](#pone.0166372.s007){ref-type="supplementary-material"}). Similarly, in case of HLA class II binders (ProPred), PDE4DIP has 7 or more neoepitopes (HLA class II), which were found in 184 cell lines ([S7 Table](#pone.0166372.s008){ref-type="supplementary-material"}). It was also found that there were 5 or more neoepitopes predicted to be positive using BCE from NR1H2, which were present in 868 cell linesrespectively ([S8 Table](#pone.0166372.s009){ref-type="supplementary-material"}).

Web-Based *In Silico* Platform {#sec007}
------------------------------

Based on the extensive evaluation of cancer neoepitopes, an *in silico* platform, Cancertope, has been developed for guiding subunit-based vaccine development, immunotherapies and other therapeutic interventions. The resource offers potential vaccine candidates and antigenic regions or epitopes, suitable for designing subunit vaccines against cancer. This web-based platform has been developed on LAMP system (Linux, Apache, MySQL, and PHP/Perl). The webserver has integrated following modules in the platform for providing valuable insights into personalized cancer immunotherapies.

Database of Neoepitopes {#sec008}
-----------------------

The database consists of the analyses carried out on 905 human cancer cell lines, where a large number of immunogenic (neoepitopes) and non-immunogenic neopeptides is reported. The mutation and immune epitope information of cancer vaccine targets has been compiled in the form of 'Cancer-specific database' ([Fig 3](#pone.0166372.g003){ref-type="fig"}). For governing the effective utilization of the database, a number of standard database tools have been integrated for easy searching, browsing and retrieval of data.

![A general workflow exhibiting the overall concept of database section of Cancertope workbench.](pone.0166372.g003){#pone.0166372.g003}

Partially Personalized Module {#sec009}
-----------------------------

This module allows user to identify potential neoepitopes for designing vaccine against a cancer cell line and tissue of a sample from their genomic data. The term partially personalized is used to describe a situation, where the query sequence (from cancer tissue of a sample) is compared with the human reference proteome in the absence of normal/healthy (from non-cancerous tissue) proteome of that particular individual. This module compares user-specified cancer proteome with reference proteome and identifies potential neoepitopes ([Fig 4](#pone.0166372.g004){ref-type="fig"}). The module allows the user to submit a single protein sequence, whole proteome or VCF file from whole genome sequencing. The server will provide output in the form of potential neoepitopes.

![The personalized module of Cancertope workbench.](pone.0166372.g004){#pone.0166372.g004}

Fully Personalized Module {#sec010}
-------------------------

This module is designed for the identification of potential neoepitope-based vaccine candidates from proteomics data of cancerous and healthy tissues of a patient. User needs to provide protein or proteome of cancerous cells (or tissues) as well as of normal cells (healthy tissue) from the same individual ([Fig 5](#pone.0166372.g005){ref-type="fig"}). It will identify neopeptides and neoepitopes present in the proteome of cancer tissue but absent in proteome of healthy tissues. Like the partially personalized module, this module also allows the user to submit a pair of protein sequences, a pair of whole proteomes or VCF files from whole genome sequencing.

![The fully personalized module of Cancertope workbench.](pone.0166372.g005){#pone.0166372.g005}

### Advanced tools {#sec011}

This module provides two menus: i) Epitope Mapping for mapping experimentally validated epitopes, and ii) Cross-Reactivity for identification of cancer-specific peptides or neopeptides. 'Epitope Mapping' menu of Cancertope allows the user to identify antigenic regions in their protein sequence. In order to identify antigenic regions, we searched experimentally validated epitopes (e.g., B-cell, T-cell, HLA binders) present in major immunological databases like IEDB \[[@pone.0166372.ref028]\], MHCBN \[[@pone.0166372.ref029]\], BCIPEP \[[@pone.0166372.ref030]\]. 'Cross-Reactivity' menu is designed for removing neopeptides that are present specifically in cancer antigen submitted by the user and not in the human genome, in order to remove cross-reactive peptides. This 'Cross-Reactivity' menu expands the utility of the platform by allowing the user to search their antigen sequence against reference protein, human reference proteome and 1000 Genomes-based proteome.

Discussion {#sec012}
==========

Although the field of personalized cancer vaccine design using patient's genomics data is in very primitive stages, the approach adopted for developing Cancertope suggests clinical as well as diagnostic potential. Since ages, cancer immunotherapy and vaccine development are being practiced as effective measures of therapeutic interventions. In 1999, Brossart *et al*. proved the potential implication of HLA-A2 restricted peptides in cancer therapies \[[@pone.0166372.ref031]\]. Although substantial growth in understanding of cancer induced by viruses such as papilloma virus and hepatitis B virus is achieved, but till date there is no significant success in the development of vaccines against these cancers. The difficulty in developing these vaccines is tolerance against self-antigens, risk of autoimmunity and heterogeneity in genomics of different cancers \[[@pone.0166372.ref032],[@pone.0166372.ref033]\]. Cancertope provides well-defined filters that possess great significance in terms of cross reactivity by eliminating epitopes located in reference protein, human reference proteomeand 1000 Genomes-based proteomes. Thus, the provided filters assist in combating the pertaining concern of autoimmunity thus specifically activating immune system against cancer.

The use of cancer cell lines for immunological studies may be critical, since in absence of immunological pressure, the genomic profile of cancer cell lines may be ambiguous. However, this possibility has been ruled out by the correlation analysis preformed by CCLE study where the genomic similarities by lineage between CCLE cell lines and primary tumors from Tumorscape, expO, MILE and COSMIC data sets were inspected. The data from mutation frequencies in 17 lineages of CCLE and COSMIC primary tumor data revealed high correlation of these mutations with most of the lineages such as breast (r = 0.73), colorectal (r = 0.76), esophagus (r = 0.95), kidney (r = 0.85), liver (r = 0.64) and pancreas (r = 0.96). Since the mutational profile of cancer cell lines demonstrated significant correlation with patient tumor sample, therefore this sequence data was selected for the conducted immunological evaluation. The proposed vaccine candidates from Cancertope were highly expressed in most of the cell lines, which makes them suitable candidates because over expression is also considered as one of the prime criterion for developing cancer vaccines \[[@pone.0166372.ref034]\].

While, the immune epitope prediction tools used in this study were highly cited, published and accurate but still these prediction algorithms have their own limitations. Thus, the neoepitope/antigens should be experimentally validated before suggesting it for medical purpose. There are following major parameters which need to be tested to validate a neoepitope: (a) HLA binding of the peptide, (b) Display of the neoepitope on the tumor surface on MHC molecule (can be verified either by mass spectrometry or by using a T cell raised against the neoepitope), (c) Expression of the neoantigen in the tumor cells and (d) cross reactivity which means T cells against the peptide should not recognize the wild-type peptide. After considering these limitations, the applied strategy in the study will be beneficial for scientific community and pharmaceutical companies. The cancer genomics in combination with computational predictions and experimental validations of immune epitopes can be used for designing successful cancer vaccines for patients. A few commercialized agencies (<http://neontherapeutics.com/>, <http://www.chordomafoundation.org/>, <http://www.vaccinogeninc.com/>, <http://gapvac.eu/> and <http://www.epivax.com/>) are already working in this direction.

The Cancertope resource delivers extensive information on cancer specific mutations and investigates the immunogenic potential of neoepitopes by employing several prediction algorithms. The database section of Cancertope stipulates all the generalized vaccine candidates that can be validated thus gearing cancer research. Additionally, the module dispensing insights into personalized vaccines (partially- and fully-personalized) for newly sequenced genome operates on the genome annotation. The annotation and immune prediction pipeline further suggests most effective vaccine candidates for the queried sequencing data. The resource also features additional options for experimental epitope mapping and removal of cross-reactive candidates valuable for determining suitable vaccine candidates.

Conclusion {#sec013}
==========

In summary, a web-based platform for predicting vaccine candidates effective against cancer is reported. The platform basically delivers two options to the users, i.e. database-specific and other being user-interactive prediction server. The database-specific service maintains neoepitopes examined in 905 cancer cell lines, which are key components for activating the immune system against cancer cell lines. Furthermore, the neoepitope-based database facilitates a demonstration for guiding the generation of neoepitopes against a tumor from its whole-genome. Although, the indicated cancer cell lines are correlated with patient tumor sample in genomic profiles yet the neoepitopes exemplified in our resource must be authorized experimentally before inclining them for clinical applications. For advancing the aim of personalized vaccine design against a patient or tissue-specific tumor, user-interactive interface has been designed by incorporating different modules. Under the user-interactive provision, server allows to identify cancer-specific epitopes against a tumor from its proteome/protein. In case, where user provides both healthy as well as tumor samples from the same patient, then the server's personalized module identifies patient-specific potential neoepitopes. Further, these putative neoepitopes can then be targeted for designing vaccines and immunotherapies against cancer thus enabling personalized therapy in real life scenario. Although the prediction methods implemented in the Cancertope pipeline are highly accurate and cited by scientific community, the experimental validation and testing of parameters like HLA binding/expression of neoepitope, cross reactivity and T cell activation, is very important before going to clinical setup. However, the predicted vaccine candidates from Cancertope have higher potential to be experimentally authenticated because of their higher reported efficacies; consequently offering cost-effective, economical, timesaving and streamlined pipeline for acclaiming personalized cancer vaccines.

Methods {#sec014}
=======

Source Data {#sec015}
-----------

The mutation profile of cancer cell lines was retrieved from Cancer Cell Line Encyclopedia (CCLE) \[[@pone.0166372.ref016]\] where MAF file was downloaded from data portal (<http://www.broadinstitute.org/ccle/data/browseData>). The selected dataset comprised the mutational profile of 1651 genes in 905 cell lines, where the variant filtration was done by exclusion of variants with low allelic fraction, common polymorphisms and putative neutral variants. Since the mutated protein sequences were not provided in CCLE database, the mutation profiles were mapped on to the reference cDNA sequences of each gene obtained from NCBI. Thereafter, the mutated cDNA of each gene was translated into mutant protein sequences. All the four types of mutations namely missense, frame shift, in-frame insertion and in-frame deletions were included in mutation profile.

Selection of Cancer Vaccine Antigens {#sec016}
------------------------------------

This section specifies the application of CanProVar (Cancer Proteome Variation) \[[@pone.0166372.ref017]\] database for selecting cancer vaccine candidates based on their cancer sensitivity. The database consists of single amino acid alterations in the human proteome and contains cancer-specific variations (cancer-sensitive mutations) and non-cancer specific variations in different proteins. First, the frequency of cancer-associated mutations (f~D~) and frequency of non-cancer specific variations (f~P~) for each protein, was computed. With a criteria of f~D~/f~P~\> = 2 and f~D~\> = 20, a total of 52 proteins were selected. These criteria were applied to select highly cancer sensitive proteins. Out of 52 proteins, only 34 proteins were found concurrent to CCLE study. These 34 proteins were then used as potential vaccine antigens or candidates and subsequently subjected to analyses via PANTHER classification system \[[@pone.0166372.ref035]\] (<http://www.pantherdb.org/>) to understand the properties of these antigens.

In addition, potential vaccine candidates were also identified from CCLE database based on their frequency of mutation. The mutational analysis revealed 26 proteins that were mutated in at least 10% (90 cell lines) of the cell lines. Finally, a total of 60 potential cancer vaccine candidates were obtained (34 cancer-associated antigens from CanProVar and 26 frequently mutated antigens from CCLE).

Generation of Neopeptides {#sec017}
-------------------------

The term neopeptide in this study is being referred to the 9-mer sequences (9 residues continuous stretch of peptide) that contain at least one cancer-associated mutation. The length of neopeptide (epitope) was fixed to nine residues as both HLA class I and class II binders have a binding core of nine residues \[[@pone.0166372.ref036],[@pone.0166372.ref037]\]. In order to identify neopeptides in a vaccine antigen, following steps were practiced: i) generated all possible overlapping peptides in an antigen, ii) removed redundant peptides and iii) removed all those peptides mapping to human reference proteome. This strategy expedited the detection of peptides exclusively present in the proteome of cancer cell lines but absent in proteome of a healthy individual.

Pipeline for Predicting Immunogenicity {#sec018}
--------------------------------------

In order to estimate the immunogenicity of these neopeptides, a pipeline was established for prediction of different types of epitopes/binders. The pipeline integrated a number of algorithms for predicting diverse immune epitopes required for activating different arms of the immune system (CD4^+^ T cells, CD8^+^ T cells, B cells). The algorithms employed in the immune epitope prediction pipeline were preferred over other prevailing algorithms on the basis of availability in the standalone state. Moreover, the predictions from these algorithms have already been verified in a few experimental as well as *in silico* studies approving high accuracy and reliability of the softwares \[[@pone.0166372.ref038],[@pone.0166372.ref039],[@pone.0166372.ref040],[@pone.0166372.ref041]\]. The immune epitope prediction can broadly be categorized into three categories.

CD8^+^ T Cell Epitopes {#sec019}
----------------------

In past, a number of methods have been reported for predicting HLA class I binders including SYFPEITHI \[[@pone.0166372.ref042]\], NetMHC \[[@pone.0166372.ref043]\], ProPred1 \[[@pone.0166372.ref024]\], and nHLAPred \[[@pone.0166372.ref025]\]. In the present study, we used standalone version of ProPred1 and nHLAPred for predicting HLA class I binders; both the algorithms predict promiscuous HLA class I binders. While, ProPred1 is a matrix-based method that predicts HLA binding sites in an antigenic sequence for 47 HLA class I alleles and nHLAPred was developed for envisaging 67 HLA class I binders using machine learning techniques. In addition to HLA class I binders as potential CTL epitopes, we also used a direct method, CTLPred, for predicting CTL epitopes. The prediction via direct method is critical as it discriminates between T cell epitopes and non-epitope MHC binders whereas HLA binding prediction only predicts the MHC binders from antigenic sequences.

CD4^+^ T Cell Epitopes {#sec020}
----------------------

Previously, a number of algorithms have been developed for predicting HLA class II binders such as ProPred \[[@pone.0166372.ref026]\], TEPITOPE \[[@pone.0166372.ref044]\] and NetMHCIIpan \[[@pone.0166372.ref045]\]. In this study, ProPred software has been used for predicting HLA class II binders. This software allows prediction of promiscuous HLA class II binders that can bind to a large number of alleles.

B Cell Epitopes {#sec021}
---------------

There are numerous methods such as BCEPred \[[@pone.0166372.ref046]\], CBtope \[[@pone.0166372.ref047]\], LBtope \[[@pone.0166372.ref027]\], Discotope \[[@pone.0166372.ref048]\], COBEpro \[[@pone.0166372.ref049]\] available for predicting B-cell epitopes. We employed a standalone version of LBtope software for the prediction of linear B-cell epitopes. In order to predict immune epitopes in the query submitted by user at run time, all the prediction tools were required in standalone form. All the standalone prediction tools chosen for the study were heavily cited and were published in journals of high repute. The prediction standalones were used at default thresholds and parameters as optimized by the original authors.

### Proteome data {#sec022}

In this study, the reference proteome and reference gene sequences were obtained from FTP portal of NCBI (<http://ftp.ncbi.nlm.nih.gov/refseq/>). In addition, the 1000 Genomes-based proteomes were generated by annotation of 1000 Genomes' VCF files (<http://ftp-trace.ncbi.nih.gov/1000genomes/ftp/release/20110521/>) through ANNOVAR package \[[@pone.0166372.ref050]\]. The mutated sequence generation was done as mentioned in the 'Source data' section above.

### Expression data {#sec023}

The expression profile of 905 cancer cell lines was obtained from CCLE database (<http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-36139/>). In order to provide inclusive expression status of vaccine candidates, the number of cell lines with varying range of expressions were calculated; for instance \> = 3 (GT3), \> = 7 (GT7), \> = 9 (GT9) and \> = 12 (GT12); expression values ranging from 2--15.

Supporting Information {#sec024}
======================

###### The gene ontological information comprising of biological process, molecular function and cellular localization of cancer sensitive proteins.

(TIFF)

###### 

Click here for additional data file.

###### The top ten most frequent neopeptides for each tissue.

For all the tissue of origin, most frequent neoepitopes were investigated and predicted for immune induction potential.

(XLSX)

###### 

Click here for additional data file.

###### Representation of the number of neopeptides present in every tissue type.

Each vaccine candidate is presented with number of unique neopeptide for each tissue of origin.

(XLSX)

###### 

Click here for additional data file.

###### List of promiscuous neoepitopes with immunological potential in the form of CTL epitope, MHC binders, number of alleles, and B cell epitope.

(XLSX)

###### 

Click here for additional data file.

###### The number of cell lines having positive CTL epitopes in different range; for example PRKDC has 836 unique cell lines having total 5 or more unique CTL epitopes.

The yellow cells present the number of neo-epitopes (CTL).

(XLSX)

###### 

Click here for additional data file.

###### The number of cell lines having positive HLA I binders (ProPred1) in different range for example RECQL4 has 672 unique cell lines having total 15 or more unique HLA I binders.

The yellow cells present the number of neo-epitopes (HLA I).

(XLSX)

###### 

Click here for additional data file.

###### The number of cell lines having positive HLA I binders (nHLAPred) in different range for example PDE4DIP has 342 unique cell lines having total 7 or more unique HLA I binders.

The yellow cells present the number of neo-epitopes (HLA I).

(XLSX)

###### 

Click here for additional data file.

###### The number of cell lines having positive HLA II binders in different range for example PRKDC has 37 unique cell lines having total 5 or more unique HLA II binders.

The yellow cells present the number of neo-epitopes (HLA II).

(XLSX)

###### 

Click here for additional data file.

###### The number of cell lines having positive B cell epitopes in different range for example NR1H2 has 868 unique cell lines having total 5 or more unique B cell epitopes.

The yellow cells present the number of neo-epitopes (BCE).

(XLSX)

###### 

Click here for additional data file.
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